SCHEMBL5876526

SCHEMBL5876526

Cc1ccc(S(=O)(=O)n2nc(C(=O)O)c3c2CC(c2ccccc2)C=C3)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.44
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
GAA P10253 3/20 0.40
TSHR P16473 2/20 0.40
MMP2 P08253 1/20 0.39
SLC9A1 P19634 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 3/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TERT O14746 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876072 0.85 NPSR1 (0.43) NPSR1NR1H2NR1H3GAATSHR
SCHEMBL5876671 0.82 NPSR1 (0.40) NPSR1NR1H2NR1H3GAATSHR
SCHEMBL5876462 0.81 MMP2 (0.39) NPSR1NR1H2NR1H3GAAMMP2
SCHEMBL5876033 0.79 MMP2 (0.38) NPSR1NR1H2NR1H3GAAMMP2
SCHEMBL5878654 0.78 CRHBP (0.39) NR1H2NR1H3GAATSHRCRHBP
Hydrochloric Acid SCHEMBL5878572 0.77 CRHBP (0.39) NR1H2NR1H3GAATSHRCRHBP
SCHEMBL5876186 0.75 CYP2C19 (0.42) NPSR1NR1H2NR1H3GAATSHR
SCHEMBL5875961 0.74 CYP2C19 (0.43) NPSR1NR1H2NR1H3GAATSHR
SCHEMBL5876231 0.72 CYP2C19 (0.39) NPSR1NR1H2NR1H3GAATSHR
SCHEMBL5875928 0.71 ALDH1A1 (0.39) NPSR1NR1H2NR1H3GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT NPSR1 797/4885NR1H2 556/4885NR1H3 456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.